Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.

Abstract excerpt

Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) is a promising target for the treatment of cancer. The FDA approved two molecular entities, ivosidenib and enasidenib, which target mIDH1 and mIDH2, respectively, for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). However, the alarming emergence of drug resistance to ivosidenib and enasidenib, a low response rate and relapse after short-term...

Topics

Join the communities discussing this publication.

• Acute Myeloid Leukemia Research
• Cancer Genomics and Diagnostics
• Combined Modality Therapy
• Enzyme Inhibitors
• Histone Deacetylase Inhibitors Research